Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 4 | 2023 | 196 | 2.020 |
Why?
|
| Intestinal Obstruction | 2 | 2021 | 39 | 1.460 |
Why?
|
| Intestines | 2 | 2023 | 325 | 0.820 |
Why?
|
| Benzocycloheptenes | 1 | 2021 | 2 | 0.740 |
Why?
|
| Intestinal Mucosa | 2 | 2022 | 532 | 0.720 |
Why?
|
| Wound Healing | 1 | 2022 | 254 | 0.690 |
Why?
|
| Triazoles | 1 | 2021 | 125 | 0.670 |
Why?
|
| Pancreatitis | 1 | 2020 | 105 | 0.650 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2021 | 224 | 0.630 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 607 | 0.570 |
Why?
|
| Fibrosis | 4 | 2023 | 452 | 0.550 |
Why?
|
| Colitis, Ulcerative | 3 | 2023 | 104 | 0.500 |
Why?
|
| MicroRNAs | 1 | 2021 | 600 | 0.480 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2023 | 284 | 0.450 |
Why?
|
| Constriction, Pathologic | 2 | 2021 | 207 | 0.350 |
Why?
|
| Inflammation | 3 | 2023 | 2465 | 0.290 |
Why?
|
| Organoids | 2 | 2022 | 74 | 0.220 |
Why?
|
| Ileum | 1 | 2023 | 92 | 0.210 |
Why?
|
| Cartilage Oligomeric Matrix Protein | 1 | 2021 | 2 | 0.190 |
Why?
|
| Deductibles and Coinsurance | 1 | 2021 | 9 | 0.190 |
Why?
|
| Piperidines | 2 | 2021 | 159 | 0.180 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 101 | 0.180 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2022 | 250 | 0.180 |
Why?
|
| Mammals | 1 | 2022 | 241 | 0.180 |
Why?
|
| Myofibroblasts | 1 | 2022 | 115 | 0.180 |
Why?
|
| Salmonella typhimurium | 1 | 2022 | 165 | 0.170 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2021 | 153 | 0.170 |
Why?
|
| Pets | 1 | 2020 | 20 | 0.170 |
Why?
|
| Stress, Mechanical | 1 | 2021 | 445 | 0.160 |
Why?
|
| Pyrimidines | 2 | 2021 | 374 | 0.160 |
Why?
|
| Clostridium Infections | 1 | 2020 | 54 | 0.160 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2019 | 13 | 0.160 |
Why?
|
| Humans | 18 | 2023 | 114078 | 0.160 |
Why?
|
| Insurance, Health | 1 | 2021 | 243 | 0.160 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2019 | 29 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2022 | 678 | 0.160 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 56 | 0.150 |
Why?
|
| Biological Products | 1 | 2021 | 166 | 0.150 |
Why?
|
| Fatty Liver | 1 | 2020 | 209 | 0.150 |
Why?
|
| Pyrroles | 1 | 2018 | 181 | 0.140 |
Why?
|
| Life Style | 1 | 2020 | 428 | 0.140 |
Why?
|
| Acute Disease | 1 | 2020 | 909 | 0.140 |
Why?
|
| Neutrophils | 1 | 2022 | 1089 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2018 | 217 | 0.130 |
Why?
|
| Computational Biology | 1 | 2020 | 528 | 0.130 |
Why?
|
| Hypoxia | 1 | 2022 | 956 | 0.130 |
Why?
|
| Computer Simulation | 1 | 2020 | 873 | 0.130 |
Why?
|
| Animals | 5 | 2023 | 31570 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 771 | 0.120 |
Why?
|
| Intracranial Aneurysm | 1 | 2016 | 90 | 0.120 |
Why?
|
| Feeding Behavior | 1 | 2020 | 572 | 0.120 |
Why?
|
| Cognition Disorders | 2 | 2009 | 476 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 784 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 502 | 0.100 |
Why?
|
| Liver | 1 | 2020 | 1633 | 0.100 |
Why?
|
| Alzheimer Disease | 2 | 2007 | 442 | 0.100 |
Why?
|
| Biomarkers | 1 | 2021 | 3397 | 0.090 |
Why?
|
| Mice | 2 | 2023 | 14847 | 0.090 |
Why?
|
| Quality of Life | 1 | 2019 | 2345 | 0.080 |
Why?
|
| Dominance, Cerebral | 1 | 2007 | 49 | 0.070 |
Why?
|
| Brain | 2 | 2009 | 2355 | 0.070 |
Why?
|
| Gyrus Cinguli | 1 | 2007 | 70 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2007 | 684 | 0.070 |
Why?
|
| Frontal Lobe | 1 | 2007 | 141 | 0.070 |
Why?
|
| Brain Mapping | 1 | 2009 | 521 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 2007 | 380 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2007 | 511 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2021 | 3007 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2021 | 12521 | 0.050 |
Why?
|
| Motivation | 1 | 2007 | 488 | 0.050 |
Why?
|
| Ustekinumab | 1 | 2023 | 12 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 2540 | 0.050 |
Why?
|
| Cognition | 1 | 2009 | 990 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2022 | 70 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2023 | 6198 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2022 | 507 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2022 | 426 | 0.040 |
Why?
|
| Colectomy | 1 | 2021 | 86 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2007 | 3039 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2019 | 2958 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2022 | 444 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6307 | 0.040 |
Why?
|
| Male | 7 | 2020 | 55418 | 0.040 |
Why?
|
| Female | 7 | 2020 | 59347 | 0.030 |
Why?
|
| Middle Aged | 4 | 2020 | 26620 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 2016 | 108 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2019 | 9051 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2021 | 1579 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2022 | 3862 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 2248 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 10458 | 0.030 |
Why?
|
| Aged | 4 | 2020 | 18973 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1205 | 0.030 |
Why?
|
| Hospitals | 1 | 2018 | 581 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 1762 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 385 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1815 | 0.020 |
Why?
|
| Prognosis | 1 | 2019 | 3315 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 4884 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 2371 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 115 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 258 | 0.020 |
Why?
|
| Surface Properties | 1 | 2009 | 385 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 30394 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 260 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 4392 | 0.020 |
Why?
|
| Atrophy | 1 | 2007 | 152 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2007 | 291 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 318 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2007 | 212 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 6077 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 739 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 926 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 8612 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 17811 | 0.010 |
Why?
|